Skip to main content
Top
Published in: Diabetologia 3/2007

Open Access 01-03-2007 | Short Communication

Does self-monitoring of blood glucose improve outcome in type 2 diabetes? The Fremantle Diabetes Study

Authors: W. A. Davis, D. G. Bruce, T. M. E. Davis

Published in: Diabetologia | Issue 3/2007

Login to get access

Abstract

Aims/hypothesis

To assess whether self-monitoring of blood glucose (SMBG) is an independent predictor of improved outcome in a community-based cohort of type 2 diabetic patients.

Materials and methods

We used longitudinal data from (1) 1,280 type 2 diabetic participants in the observational Fremantle Diabetes Study (FDS) who reported SMBG and diabetes treatment status at study entry (1993–1996), and (2) a subset of 531 participants who attended six or more annual assessments (referred to as the 5-year cohort). Diabetes-related morbidity, cardiac death and all-cause mortality were ascertained at each assessment, supplemented by linkage to the Western Australian Data Linkage System.

Results

At baseline, 70.2% (898 out of 1,280) of type 2 patients used SMBG. During 12,491 patient-years of follow-up (mean 9.8 ± 3.5 years), 486 (38.0%) type 2 participants died (196 [15.3%] from cardiac causes). SMBG was significantly less prevalent in those who died during follow-up than in those who were still alive at the end of June 2006 (65.4 vs 73.0%, p = 0.005). In Cox proportional hazards modelling, after adjustment for confounding and explanatory variables, SMBG was not independently associated with all-cause mortality, but was associated with a 79% increased risk of cardiovascular mortality in patients not treated with insulin. For the 5-year cohort, time-dependent SMBG was independently associated with a 48% reduced risk of retinopathy.

Conclusions/interpretation

SMBG was not independently associated with improved survival. Inconsistent findings relating to the association of SMBG with cardiac death and retinopathy may be due to confounding, incomplete covariate adjustment or chance.
Literature
1.
go back to reference Gray A, Raikou M, McGuire A et al (2000) Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised control trial (UKPDS 41). BMJ 320:1373–1378PubMedCrossRef Gray A, Raikou M, McGuire A et al (2000) Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised control trial (UKPDS 41). BMJ 320:1373–1378PubMedCrossRef
2.
go back to reference Ipp E, Aquino RL, Christenson P (2005) Point: self-monitoring of blood glucose in type 2 diabetic patients not receiving insulin. The sanguine approach. Diabetes Care 28:1528–1530PubMed Ipp E, Aquino RL, Christenson P (2005) Point: self-monitoring of blood glucose in type 2 diabetic patients not receiving insulin. The sanguine approach. Diabetes Care 28:1528–1530PubMed
3.
go back to reference Davidson MB (2005) Counterpoint: self-monitoring of blood glucose in type 2 diabetic patients not receiving insulin. A waste of money. Diabetes Care 28:1531–1533PubMed Davidson MB (2005) Counterpoint: self-monitoring of blood glucose in type 2 diabetic patients not receiving insulin. A waste of money. Diabetes Care 28:1531–1533PubMed
4.
go back to reference Martin S, Schneider B, Heinemann L et al (2006) Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study. Diabetologia 49:271–278PubMedCrossRef Martin S, Schneider B, Heinemann L et al (2006) Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study. Diabetologia 49:271–278PubMedCrossRef
5.
go back to reference Davis WA, Bruce DG, Davis TME (2006) Is self-monitoring of blood glucose appropriate for all type 2 diabetic patients? The Fremantle Diabetes Study. Diabetes Care 29:1764–1770PubMedCrossRef Davis WA, Bruce DG, Davis TME (2006) Is self-monitoring of blood glucose appropriate for all type 2 diabetic patients? The Fremantle Diabetes Study. Diabetes Care 29:1764–1770PubMedCrossRef
6.
go back to reference Davis TM, Zimmet P, Davis WA, Bruce DG, Fida S, Mackay I (2000) Autoantibodies to glutamic acid decarboxylase in diabetic patients from a multiethnic Australian community: the Fremantle Diabetes Study. Diabet Med 17:667–674PubMedCrossRef Davis TM, Zimmet P, Davis WA, Bruce DG, Fida S, Mackay I (2000) Autoantibodies to glutamic acid decarboxylase in diabetic patients from a multiethnic Australian community: the Fremantle Diabetes Study. Diabet Med 17:667–674PubMedCrossRef
7.
go back to reference Norman PE, Davis WA, Bruce DG, Davis TM (2006) Peripheral arterial disease and risk of cardiac death in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care 29:575–580PubMedCrossRef Norman PE, Davis WA, Bruce DG, Davis TM (2006) Peripheral arterial disease and risk of cardiac death in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care 29:575–580PubMedCrossRef
8.
go back to reference Holman CD, Bass AJ, Rouse IL, Hobbs MS (1999) Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust N Z J Public Health 23:453–459PubMed Holman CD, Bass AJ, Rouse IL, Hobbs MS (1999) Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust N Z J Public Health 23:453–459PubMed
9.
go back to reference Bradshaw PJ, Jamrozik K, Jelfs P, Le M (2000) Mobile Australians: a moving target for epidemiologists. Med J Aust 172:566, (Letter)PubMed Bradshaw PJ, Jamrozik K, Jelfs P, Le M (2000) Mobile Australians: a moving target for epidemiologists. Med J Aust 172:566, (Letter)PubMed
10.
go back to reference Davis WA, Norman PE, Bruce DG, Davis TM (2006) Predictors, consequences and costs of diabetes-related lower extremity amputation complicating type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 49:2634–2641PubMedCrossRef Davis WA, Norman PE, Bruce DG, Davis TM (2006) Predictors, consequences and costs of diabetes-related lower extremity amputation complicating type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 49:2634–2641PubMedCrossRef
Metadata
Title
Does self-monitoring of blood glucose improve outcome in type 2 diabetes? The Fremantle Diabetes Study
Authors
W. A. Davis
D. G. Bruce
T. M. E. Davis
Publication date
01-03-2007
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 3/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0581-0

Other articles of this Issue 3/2007

Diabetologia 3/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.